Trimel intends to use the Dunwin facility to manufacture clinical supplies for its CompleoTRT and TBS-2 (Anorgasmia) products.
The company intends to use Dunwin facility to even the balance its pipeline including those compounds under development with the TriVair pulmonary delivery system.
Trimel has demonstrated to Health Canada that the activities it conducts at its Dunwin facility conform to the Food and Drugs Act and its associated regulations.
Trimel chairman and CEO Bruce Brydon said that the company has now achieved first step toward the commercial supply of its products with the strictest adherence to quality.